Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer.

Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH.

Breast Cancer Res Treat. 2012 Oct;135(3):681-92. doi: 10.1007/s10549-012-2148-8. Epub 2012 Aug 10.

PMID:
22878889
2.

Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH.

Breast Cancer Res. 2014 Jan 29;16(1):R15. doi: 10.1186/bcr3609.

3.

Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.

Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A.

Breast Cancer Res Treat. 2015 Aug;152(3):499-508. doi: 10.1007/s10549-015-3442-z. Epub 2015 Jul 2.

PMID:
26133921
4.

AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.

Wong C, Wang X, Smith D, Reddy K, Chen S.

Breast Cancer Res Treat. 2012 Jul;134(2):671-81. doi: 10.1007/s10549-012-2105-6. Epub 2012 Jun 16.

5.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA.

Breast Cancer Res. 2015 Jan 30;17:13. doi: 10.1186/s13058-015-0515-1.

6.

Aromatase inhibitors and xenograft studies.

Chumsri S, Sabnis GJ, Howes T, Brodie AM.

Steroids. 2011 Jul;76(8):730-5. doi: 10.1016/j.steroids.2011.02.033. Epub 2011 Mar 21.

7.

Molecular characterization of anastrozole resistance in breast cancer: pivotal role of the Akt/mTOR pathway in the emergence of de novo or acquired resistance and importance of combining the allosteric Akt inhibitor MK-2206 with an aromatase inhibitor.

Vilquin P, Villedieu M, Grisard E, Ben Larbi S, Ghayad SE, Heudel PE, Bachelot T, Corbo L, Treilleux I, Vendrell JA, Cohen PA.

Int J Cancer. 2013 Oct 1;133(7):1589-602. doi: 10.1002/ijc.28182. Epub 2013 May 2.

8.

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling.

Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM.

Br J Cancer. 2010 Mar 2;102(5):815-26. doi: 10.1038/sj.bjc.6605553. Epub 2010 Feb 9.

9.

Aromatase and breast cancer.

Brodie A, Sabnis G, Jelovac D.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102.

10.

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE.

Int J Oncol. 2015 Apr;46(4):1481-90. doi: 10.3892/ijo.2015.2850. Epub 2015 Jan 26.

11.

Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells.

Chen Z, Wang Y, Warden C, Chen S.

J Steroid Biochem Mol Biol. 2015 May;149:118-27. doi: 10.1016/j.jsbmb.2015.02.004. Epub 2015 Feb 12.

12.

Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.

Chen Z, Yuan YC, Wang Y, Liu Z, Chan HJ, Chen S.

Breast Cancer Res Treat. 2015 Jul;152(1):29-39. doi: 10.1007/s10549-015-3446-8. Epub 2015 May 31.

13.

Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.

Zhang W, Ding W, Chen Y, Feng M, Ouyang Y, Yu Y, He Z.

Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.

PMID:
21712253
14.

Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.

Sabnis G, Brodie A.

Clin Breast Cancer. 2010 Feb;10(1):E6-E15. doi: 10.3816/CBC.2010.n.014.

PMID:
20133251
15.

Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).

Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S.

Breast Cancer Res Treat. 2013 Jan;137(1):93-107. doi: 10.1007/s10549-012-2332-x. Epub 2012 Nov 18.

16.

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.

Curley MD, Sabnis GJ, Wille L, Adiwijaya BS, Garcia G, Moyo V, Kazi AA, Brodie A, MacBeath G.

Mol Cancer Ther. 2015 Nov;14(11):2642-52. doi: 10.1158/1535-7163.MCT-15-0169. Epub 2015 Aug 26.

17.

The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells.

Masri S, Liu Z, Phung S, Wang E, Yuan YC, Chen S.

Breast Cancer Res Treat. 2010 Nov;124(1):89-99. doi: 10.1007/s10549-009-0716-3. Epub 2010 Jan 7.

18.

HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.

Sabnis GJ, Goloubeva OG, Kazi AA, Shah P, Brodie AH.

Mol Cancer Ther. 2013 Dec;12(12):2804-16. doi: 10.1158/1535-7163.MCT-13-0345. Epub 2013 Oct 3.

19.

Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.

Thomsen KG, Lyng MB, Elias D, Vever H, Knoop AS, Lykkesfeldt AE, Lænkholm AV, Ditzel HJ.

Breast Cancer Res Treat. 2015 Dec;154(3):483-94. doi: 10.1007/s10549-015-3644-4. Epub 2015 Nov 19.

PMID:
26585578
20.

GP88 (PC-Cell Derived Growth Factor, progranulin) stimulates proliferation and confers letrozole resistance to aromatase overexpressing breast cancer cells.

Abrhale T, Brodie A, Sabnis G, Macedo L, Tian C, Yue B, Serrero G.

BMC Cancer. 2011 Jun 9;11:231. doi: 10.1186/1471-2407-11-231.

Supplemental Content

Support Center